{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:05:36Z","timestamp":1786118736724,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1097\/fpc.0b013e3281eb8f07","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T06:28:01Z","timestamp":1209882481000},"page":"803-811","source":"Crossref","is-referenced-by-count":8,"title":["Interaction between \u03b22 adrenergic receptor polymorphisms determines the extent of isoproterenol-induced vasodilatation ex vivo"],"prefix":"10.1097","volume":"17","author":[{"given":"Jawad M.","family":"Khalaila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Elami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoseph","family":"Caraco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210212","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nrg1428","article-title":"Pharmacogenetics-five decades of therapeutic lessons from genetic diversity","volume":"5","author":"Meyer","year":"2004","journal-title":"Nat Rev Genet"},{"key":"R2-2-20210212","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N Engl J Med"},{"key":"R3-2-20210212","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00008571-200309000-00001","article-title":"Drug receptor\/effector polymorphisms and pharmacogenetics: current status and challenges","volume":"13","author":"Johnson","year":"2003","journal-title":"Pharmacogenetics"},{"key":"R4-2-20210212","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/14622416.5.7.803","article-title":"Pharmacogenomics of adrenoceptors","volume":"5","author":"Flordellis","year":"2004","journal-title":"Pharmacogenomics"},{"key":"R5-2-20210212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00210-003-0824-2","article-title":"Beta-adrenoceptor polymorphisms","volume":"369","author":"Leineweber","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R6-2-20210212","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/00008571-200411000-00001","article-title":"The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines","volume":"14","author":"La Rosee","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R7-2-20210212","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jaci.2005.11.012","article-title":"Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation","volume":"117","author":"Johnson","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"R8-2-20210212","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev.pharmtox.43.100901.135823","article-title":"Pharmacology and physiology of human adrenergic receptor polymorphisms","volume":"43","author":"Small","year":"2003","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R9-2-20210212","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1165\/ajrcmb\/8.3.334","article-title":"Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects","volume":"8","author":"Reihsaus","year":"1993","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R11-2-20210212","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1046\/j.1365-2125.1999.00082.x","article-title":"Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu and Thr164Ile polymorphisms in the beta2-adrenergic receptor among Turks","volume":"48","author":"Aynacioglu","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"R12-2-20210212","first-page":"511","article-title":"Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African\u2013American, Caucasian and Chinese individuals","volume":"9","author":"Xie","year":"1999","journal-title":"Pharmacogenetics"},{"key":"R13-2-20210212","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1021\/bi00198a006","article-title":"Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties","volume":"33","author":"Green","year":"1994","journal-title":"Biochemistry"},{"key":"R14-2-20210212","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1165\/ajrcmb.13.1.7598936","article-title":"Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells","volume":"13","author":"Green","year":"1995","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R15-2-20210212","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1161\/01.HYP.36.3.371","article-title":"Beta(2)-adrenoceptor polymorphism determines vascular reactivity in humans","volume":"36","author":"Cockcroft","year":"2000","journal-title":"Hypertension"},{"key":"R16-2-20210212","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1113\/jphysiol.2002.031138","article-title":"Beta(2)-adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans","volume":"546","author":"Garovic","year":"2003","journal-title":"J Physiol"},{"key":"R17-2-20210212","first-page":"537","article-title":"Beta2-adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals","volume":"139","author":"Hoit","year":"2000","journal-title":"Am Heart J"},{"key":"R18-2-20210212","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1161\/01.HYP.33.6.1425","article-title":"Beta-2 adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians","volume":"33","author":"Gratze","year":"1999","journal-title":"Hypertension"},{"key":"R19-2-20210212","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1056\/NEJMoa010819","article-title":"The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization","volume":"345","author":"Dishy","year":"2001","journal-title":"N Engl J Med"},{"key":"R20-2-20210212","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0009-9236(03)00188-7","article-title":"Genotype-dependent time course of lymphocyte beta 2-adrenergic receptor down-regulation","volume":"74","author":"Bruck","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R21-2-20210212","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1023\/A:1013354025731","article-title":"Beta2-adrenergic receptor genotype-related changes in cAMP levels in peripheral blood mononuclear cells after multiple-dose oral procaterol","volume":"18","author":"Makimoto","year":"2001","journal-title":"Pharm Res"},{"key":"R22-2-20210212","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.clpt.2005.06.002","article-title":"Human beta2-adrenergic receptor gene haplotypes and venodilation in vivo","volume":"78","author":"Bruck","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R23-2-20210212","doi-asserted-by":"crossref","first-page":"10483","DOI":"10.1073\/pnas.97.19.10483","article-title":"Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness","volume":"97","author":"Drysdale","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R24-2-20210212","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/01.fpc.0000114763.78957.ec","article-title":"Beta2-adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo","volume":"14","author":"Dishy","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R25-2-20210212","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1056-8719(00)00121-0","article-title":"Techniques to study the pharmacodynamics of isolated large and small blood vessels","volume":"44","author":"Angus","year":"2000","journal-title":"J Pharmacol Toxicol Methods"},{"key":"R26-2-20210212","first-page":"H1482","article-title":"Endothelial dysfunction in human intramyocardial small arteries in atherosclerosis and hypercholesterolemia","volume":"275","author":"Cooper","year":"1998","journal-title":"Am J Physiol"},{"key":"R27-2-20210212","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/0003-4975(89)90027-1","article-title":"Incidence of atherosclerosis in the internal mammary artery","volume":"47","author":"Sisto","year":"1989","journal-title":"Ann Thorac Surg"},{"key":"R28-2-20210212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2006.06.012","article-title":"Statins and the endothelium","volume":"46","author":"Ii","year":"2007","journal-title":"Vascul Pharmacol"},{"key":"R29-2-20210212","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/01.CIR.94.3.258","article-title":"Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (trial on reversing endothelial dysfunction) study","volume":"94","author":"Mancini","year":"1996","journal-title":"Circulation"},{"key":"R30-2-20210212","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0008-6363(98)00341-1","article-title":"Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids","volume":"42","author":"Verhaar","year":"1999","journal-title":"Cardiovasc Res"},{"key":"R31-2-20210212","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/01.CIR.88.5.2149","article-title":"Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults","volume":"88","author":"Celermajer","year":"1993","journal-title":"Circulation"},{"key":"R32-2-20210212","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.diabres.2006.07.033","article-title":"Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone","volume":"76","author":"Suzuki","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"R33-2-20210212","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.diabres.2003.08.010","article-title":"Genotype Gly\/Gly of the Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with elevated fasting serum insulin concentrations, but not with acute insulin response to glucose, in type 2 diabetic patients","volume":"63","author":"Ikarashi","year":"2004","journal-title":"Diabetes Res Clin Pract"},{"key":"R34-2-20210212","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.amjhyper.2005.01.006","article-title":"Beta2-adrenoceptor polymorphisms relate to insulin resistance and sympathetic overactivity as early markers of metabolic disease in nonobese, normotensive individuals","volume":"18","author":"Masuo","year":"2005","journal-title":"Am J Hypertens"},{"key":"R35-2-20210212","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1172\/JCI119732","article-title":"Insulin modulation of an endothelial nitric oxide component present in the alpha2- and beta-adrenergic responses in human forearm","volume":"100","author":"Lembo","year":"1997","journal-title":"J Clin Invest"},{"key":"R36-2-20210212","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00008571-200309000-00002","article-title":"An Ile to Met polymorphism in the catalytic domain of adenylyl cyclase type 9 confers reduced beta2-adrenergic receptor stimulation","volume":"13","author":"Small","year":"2003","journal-title":"Pharmacogenetics"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0b013e3281eb8f07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:39:18Z","timestamp":1786034358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01213011-200710000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e3281eb8f07","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}